Skip to main content
Top
Published in: Critical Care 1/2004

01-02-2004 | Poster presentation

The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS

Authors: J Vincent, G Bernard, J Dhainaut, M Levy, A Wheeler, W Macias

Published in: Critical Care | Special Issue 1/2004

Login to get access

Excerpt

Treatment with Drotrecogin alfa (activated) (DrotAA) in a phase 3 clinical trial (PROWESS, n = 1690) was associated with a significant survival advantage and favorable benefit–risk profile compared with placebo in adult patients with severe sepsis. A global, single-arm, open-label trial of DrotAA in adult patients with severe sepsis was subsequently conducted at 361 sites in 25 countries (ENHANCE, n = 2378). Here, the efficacies of DrotAA in ENHANCE and PROWESS were compared, with all-cause mortality at 28 days as the primary study endpoint. …
Metadata
Title
The efficacy of Drotrecogin alfa (activated) during a global, single-arm, open-label trial in adult patients with severe sepsis (ENHANCE): comparisons with PROWESS
Authors
J Vincent
G Bernard
J Dhainaut
M Levy
A Wheeler
W Macias
Publication date
01-02-2004
Publisher
BioMed Central
Published in
Critical Care / Issue Special Issue 1/2004
Electronic ISSN: 1364-8535
DOI
https://doi.org/10.1186/cc2581

Other articles of this Special Issue 1/2004

Critical Care 1/2004 Go to the issue